戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng evidence supporting a role for B cells in tumor immunology.
2 ys a central role in infectious diseases and tumor immunology.
3  ideal combination cancer therapies based on tumor immunology.
4 cant clinical implications to both viral and tumor immunology.
5 d the potentially important role of CD200 in tumor immunology.
6 in the fields of infection, vaccination, and tumor immunology.
7 dysfunction remains an unresolved problem of tumor immunology.
8 priming of antitumor CTL is well accepted in tumor immunology.
9 ranslated may have important implications in tumor immunology.
10 dels has lagged behind developments in human tumor immunology.
11 luding infectious diseases, autoimmunity and tumor immunology.
12 ct immune systems are vital to understanding tumor immunology.
13 ntification and provided novel insights into tumor immunology.
14  assessment can broaden our understanding of tumor immunology.
15 e relevance for infection, autoimmunity, and tumor immunology.
16 ith the potential for both basic research in tumor immunology and clinical stratification of patients
17 eld that could provide crucial insights into tumor immunology and encourage the effective application
18                               This fusion of tumor immunology and genetics is leading to new ways to
19 overy that will be useful for studying basic tumor immunology and identifying new targets for immunot
20 ith worsened prognosis; however, its role in tumor immunology and immune checkpoint therapy (ICT) is
21  has already influenced our understanding of tumor immunology and immunotherapy.
22  important information for understanding the tumor immunology and metabolism of MBC.
23       Over the past two decades, progress in tumor immunology and targeted therapy has reshaped oncol
24  considers insights into basic neurobiology, tumor immunology, and autoimmune neuronal degeneration o
25 ficant clinical importance for autoimmunity, tumor immunology, and infectious disease.
26 ces in our understanding of basic aspects of tumor immunology, and suggest how these insights can lea
27 dvances in hematopoiesis, stem cell biology, tumor immunology, and T-cell biology.
28 s of nuclear receptors in cancer biology and tumor immunology, and underscore the current advances of
29                   Although evidence from the tumor immunology arena documented the existence of nonco
30                                              Tumor immunology-based cancer immunotherapy has become o
31 d in a series of AACR conferences, entitled "Tumor Immunology: Basic and Clinical Advances," was held
32 These antigens are of particular interest in tumor immunology, because their expression, with excepti
33  The eight articles in this Review series on tumor immunology discuss the mechanisms underlying immun
34 rscore the importance of understanding basic tumor immunology for successful clinical translation in
35 ials and some recent advances in fundamental tumor immunology give hope for improvement in future the
36  role of T cells and natural killer cells in tumor immunology has been established, less is known abo
37                                              Tumor immunology has been studied extensively.
38 e much of the focus on T cell dysfunction in tumor immunology has been, and appropriately so, on brea
39 mor cells and specimens, its precise role in tumor immunology has not been defined.
40              In addition, recent advances in tumor immunology have broadened our understanding of the
41                    Concurrently, advances in tumor immunology have led to the development of immunomo
42      However, several recent key advances in tumor immunology have now turned the tide in favor of im
43                                   Studies in tumor immunology have relied upon the classic paradigm o
44 umor cells and a heightened understanding of tumor immunology have resulted in efforts to activate ho
45 d by new discoveries in mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and materi
46 ms biologists have turned their attention to tumor immunology in an effort to understand the precise
47 Great progress has been made in the field of tumor immunology in the past decade, but optimism about
48 witnessed a major revolution in the field of tumor immunology including clinical progress using vario
49                            Recent studies in tumor immunology indicate that malignant cells frequentl
50 o underpin numerous aspects of inflammation, tumor immunology, infectious disease, and autoimmunity,
51                         A major challenge in tumor immunology is how best to activate the relatively
52                                 A paradox of tumor immunology is that tumor-infiltrating lymphocytes
53                           A major agenda for tumor immunology is the generation of specific immune re
54                                              Tumor immunology is undergoing a renaissance due to the
55                                One enigma in tumor immunology is why animals bearing malignant grafts
56                                           In tumor immunology, it has always been postulated that tum
57                              This paradox in tumor immunology led us to address two questions: (a) Do
58  evaluating immunotherapies and for defining tumor immunology paradigms.
59 ounding CRISPR screens within the context of tumor immunology, provide essential components needed to
60            The majority of lncRNAs' roles in tumor immunology remain elusive.
61 ential roles of certain nuclear receptors in tumor immunology, suggesting the possibility for them to
62   However, one of the fundamental aspects of tumor immunology-the initiation of antitumor immunity-is